The online market is a vast place where thousands of business try to fight for the attention from customers that like when they can purchase drugs for a low price and receive them in a timely manner. However, there are many problems with online pharmacies that we cannot ignore. While the history of pharmaceuticals sold via the internet is a story of a huge success celebrated by both manufacturers and customers, there are issues that we cannot overlook.

Due to the fact that there are simply too many companies and too many online pharmacies, choosing the most reliable company is hard. My Canadian Pharmacy Online mycanadianpharmacymall.com has a noble purpose. We want to make sure that our visitors have an access to a wide variety of branded and generic drugs and purchase them without bothering with the quality. This is a very important service today. How did we end up with a situation when having a reliable advisor like My Canadian Online Pharmacy is imperative?

The Beginning

Just like any other domain, pharmaceutical industry was ruled by several huge corporations that dictated both pricing and distribution methods heavily limiting the access to their products. Due to various corporate policies employed by British Company or Roche, many patients could not receive drugs that they needed. Some could not afford them. Some simple could not purchase them anywhere. The problem with corporations is that they don’t care about people and shrink their ethics to a size of a walnut when it comes to providing something for free or for a lower price when bigger profits can be made.

This led to a very concerning situation specifically in North America. In 1998, Sildenafil AKA Viagra was released in USA after being approved by FDA. This was a drug that changed how men perceived their impotence. Before sildenafil, men believed that impotence is a sentence. However, Viagra changed that and men could use a modern medication to counteract one of the most concerning issues – erectile dysfunction.

One of the problems with the release was the price. The drug was dramatically overpriced and many people simply could not afford to use it. The saving grace was that the drug is a when-needed medication. Some men could purchase several pills and use them across the whole month. Nonetheless, for the vast majority of men this was not even close to an efficient solution.

The Arrival

In parallel with British Company, other companies studied sildenafil and tried to create drugs based on the compound. In 1998, FDA approved sildenafil and British Company started distributing it under the brand Viagra. In 2000s, a plethora of new PDE5 inhibitors arrived to the marker. Cialis and Levitra are most notable additions to the market. Three companies took a commanding position in the North American market and controlled the market for over a decade.

Within first 5 years after the sensational release of Viagra in USA, the world became accustomed not only with the term Viagra, but also with a looser term Viagra Professional. We obviously talk about generics of the drug that were developed by Indian and Turkish pharmaceutical companies and sold primarily in SEA region, Africa, and Europe. At that time, generics were less popular and people simple did not know much about them.

However, the reign of generic drugs was inevitable. There were distinct advantages to generics:

• Due to lower administrative and operational expenses, manufacturers priced their generics democratically allowing more customers to afford them;
• New marketing and distribution channels started to appear namely the internet and selling VIA mail which made shopping simpler;
• The variety of dosages was much more versatile, Viagra Professional is available in various dosages including 25mg, 50mg, and even 100mg;
• The competition created by generics forced many companies to rethink their pricing patterns and lower their prices.

This was the moment for the internet to step up. In 2007, we observed a rapidly growing market where many companies operated without any control and oversight. We decided to create a company that would follow a set of standards and ethics that could be defined as a “reliable and responsible service”. For over 10 years, we have been analyzing the market, searching for the best products, and testing them continuously in order to ensure that our customers enjoy the best service and effective medications.

The Sea of Information. The Sea of Issues

Many specialists and industry experts justly pointed out that many companies were highly unreliable and tried to sell expired drugs or fakes. At the same time, some manufacturers are definitely shadier than others. This means that many customers who purchase drugs online end up becoming victims to scams and irresponsible online merchants. This problem is why My Canadian Pharmacy became so popular amongst men all over the world.

Viagra is not a drug that can be substituted with a placebo zero-effect pill. However, some irresponsible sellers believe so and sell fakes to their clients. This makes the whole industry look bad. The issue with scams blossoms on the rich soil of oversaturation of information in the internet. We simply have too much information to handle and too many companies competing for top spots in search results. This means that many trash tier companies manage to break through and compromise the whole market.

My Canadian Pharmacy was created to filter out irresponsible retailers and search for the best products out there. We test all our products, inspect how the delivery works, ensure high quality customer support, and constantly renew our partnerships. Only by constantly processing data and analyzing it, we can stay afloat in the sea of information that is internet today.

Simultaneously, we help thousands of active internet users to filter out bad offers and search for the most profitable and efficient deals without compromising quality. You can pick from a wide assortment of offers and enjoy regular bonuses, seasonal deals, and promotions including free shipments, free consultations, and reliable customer support.

Online Shopping VS Land Based Pharmacies

Various studies show that in USA only people save up to 80% by purchasing drugs and their generic versions online. On average, customers save about 65% on each deal. Before the internet, people started using international mail to purchase drugs from Thailand, India, Turkey, and other countries. Many smart people purchased drugs in Mexico for personal usage. Some US citizens purchase drugs in Canada where pharmaceuticals slightly cheaper on average. Canadians often can use online pharmacies freer than Americans.

Shopping online is much easier. If you need Viagra Professional, check various options at My Canadian Pharmacy Online and enjoy your right choice!

In an attempt to elucidate the effects of corticosteroids on extracellular matrix gene expression, we studied the expression of fibronectin in fibroblasts treated Sildenafil online with FP. Fibronectin is an extracellular matrix glycoprotein that is highly expressed in acute and chronic forms of lung injury including COPD, asthma, and many interstitial lung diseases. Villiger et al demonstrated an increase in the production of fibronectin in alveolar macrophages obtained from smokers when compared to nonsmokers. Alveolar macrophages from patients with chronic bronchitis spontaneously released greater amounts of fibronec-tin than those from asthmatic patients and control subjects. The levels of fibronectin have been correlated with a decrease in pulmonary function in smokers with COPD. In asthma, airway wall remodeling is not only associated with increased deposition of extracellular matrices, but also with alterations in the composition of the airway wall connective tissue with increased deposition of fibronectin. The aforementioned studies have implicated excessive production of fibronectin as a marker of activation of tissue remodeling and a potential mechanism for promoting fibroproliferation in tobacco-related lung disease.

The bottom row is the carbohydrate group, with food that supplies us with energy in the form of glucose. This includes cereal, bread, potatoes, pasta, rice and grains. This is the largest group and six or more portions are recommended each day (up to twelve portions if you are very active). Wholegrains should be chosen where possible.

Health and care medications for sale – buy in CanadianHealthCareMalll.Com.

Wholegrains

These foods are a good source of fibre and complex carbohydrates. Wholegrains are also a good source of vitamins and minerals, which are beneficial for maintaining a healthy blood pressure level and heart health. These include selenium, zinc, magnesium, iron, niacin, riboflavin, thiamine and Vitamin E.

As an example, brown rice has the same fat, protein and calories as white rice but also has additional fibre, calcium, iron, zinc and folic acid as well as Vitamins Bl, B2 and B6. It can help normalise blood sugar and is thought to be particularly good for the bowel, perhaps helping to lower the risk of bowel cancer. It can also lower blood cholesterol levels.

Ground flaxseed is an excellent way to add wholegrain to your diet. These small brown seeds can be crushed or ground in a food processor or coffee maker and added to food, e.g. a teaspoonful in hot cereal or yogurt. Flax seeds are high in fibre and also in omega-3.

Simple ways to increase the amount of wholegrains in your diet are shown below.

• Fruit and vegetables make up the second largest group in the food pyramid and it is recommended that we eat at least five portions of fruit and vegetables per day. We should all eat more fresh fruit and vegetables. However, many Irish men fall short on this one. Fruit and vegetables are excellent for your health for a number of reasons. Firstly, they are an excellent source of vitamins and minerals and are naturally Viagra Jelly in Australia low in calories. Secondly, they are high in soluble fibre, which can lower cholesterol and help prevent heart disease. Thirdly, fresh fruit and vegetables are very rich in antioxidants, which can help prevent heart disease and cancer. Berries are a particularly rich natural source of antioxidants, especially blueberries. Broccoli is a rich vegetable source of antioxidants and as such is called a ‘superfood’. Fourthly, they can be quite filling, which means less space for high-fat foods. The key with fruit and vegetables is to eat them often, ideally with every meal. Keeping fresh fruit in a bowl in the kitchen or freshly chopped carrots or broccoli in the fridge makes a healthy snack readily available. The only fruit and vegetables to avoid would be vegetables in creamy sauces, fried vegetables in batter and canned fruit with heavy sweet syrup. Otherwise, for fruit and veg the sky’s the limit.

Pulmatrix’s iSPERSE inhaled drug platform showed multi-drug delivery abilities and superiority over conventional lactose blending for an effective therapeutic dose of the active ingredients in Advair, salmeterol and fluticasone, as well as an additional anticholinergic bronchodilator.

iSPERSE is a novel inhaled dry powder delivery platform developed by Pulmatrix for use in the delivery of drugs via inhalation for local or systemic applications.

The preclinical data of iSPERSE suggested that it can efficiently deliver consistent double- and triple-combination drug doses and offers improved drug efficacy and safety for patients having both normal and lower or impaired lung function.

In the in vitro and preclinical studies, an iSPERSE fluticasone and salmeterol combination was matched to commercially available Advair Diskus, which contains the fluticasone and salmeterol combination blended with lactose to enable pulmonary delivery.

iSPERSE demonstrated improved delivery efficiency over Advair Diskus, as iSPERSE was shown to deliver over 2 times more lung dose of the active pharmaceutical ingredients than Advair Diskus.

In addition, iSPERSE behaved flow rate independently at flow rates of 28.3 and 60.0 LPM, maintaining a similar fine particle fraction when tested via actuation from a capsule-based passive dry powder inhaler.

Collins Stewart Analysts Reiterate a “Buy” Rating on Impax Laboratories (IPXL)

Impax Laboratories (NASDAQ: IPXL)‘s stock had its “buy” rating reaffirmed by equities research analysts at Collins Stewart in a research note issued to investors on Tuesday.

Separately, analysts at Canaccord Genuity reiterated a “hold” rating on shares of Impax Laboratories in a research note to investors on Tuesday. Analysts at Piper Jaffray (NYSE: PJC) reiterated an “overweight” rating on shares of Impax Laboratories in a research note to investors on Thursday, December 1st. They now have a $32.00 price target on the stock.

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals. In the generic pharmaceuticals market, the Company focuses on controlled-release generic versions of brand-name pharmaceuticals, covering a range of therapeutic areas. In the brand-name pharmaceuticals market, the Company is developing products for the treatment of central nervous system (CNS) disorders.

Raptor Pharmaceutical Corp. Provides Program Update on RP103 (DR Cysteamine) for Nephropathic Cystinosis

Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) RPTP
-1.91% announced today a program
update for its lead investigational compound, RP103 for the potential treatment of nephropathic cystinosis. RP103 is Raptor’s proprietary, enteric-coated, microbead delayed-release oral formulation of cysteamine bitartrate designed to potentially reduce dosing frequency and reduce gastrointestinal side effects associated with the currently approved immediate-release cysteamine bitartrate.

Following the successful completion of Raptor’s pivotal Phase 3 clinical trial of RP103, which was announced in July 2011, the Company has been conducting a planned voluntary extension study to monitor white blood cell (“WBC”) cystine levels and collect long-term safety and quality of life data. Of the 40 patients who entered the safety study after completing the Phase 3 clinical trial, 38 are currently still enrolled. All of these 38 patients have now been taking RP103 in the extension study for at least 6 months, with some patients having been in the extension study for as long as 15 months. Raptor intends to include at least 6 months of safety data for all Phase 3 completers who remain in the extension study, with its New Drug Application (“NDA”) and Marketing Authorization Application (“MAA”) filings that are expected to be filed in the first calendar quarter of 2012. The Company plans to keep the extension study open to all enrolled patients until RP103 becomes locally commercially available.

Based on the positive results of Raptor’s Phase 3 clinical trial and on the findings of its bioequivalence study, which demonstrated similar drug exposure whether administered in whole capsule or sprinkled onto applesauce, US and European regulatory agencies approved the Company’s expanded enrollment in the extension study to include patients who did not qualify for the Phase 3 clinical trial. These patients include children 1-6 years old and patients who have undergone a kidney transplant. Ten of an anticipated 18 additional patients have already enrolled in the expanded extension study. The Company also plans to study RP103 in cystinosis patients who have either stopped taking or have not been adequately controlled with the currently-marketed, immediate-release cysteamine bitartrate. While the data for these additional patient groups are not required to be included in Raptor’s NDA and MAA filings, the Company expects to include them in subsequent updates to these marketing applications.

“The data from these additional study patients will be helpful for physicians in determining optimal treatments in a broader population of patients with nephropathic cystinosis than we were able to study in our Phase 3 clinical trial,” said Patrice P. Rioux, M.D. Ph.D., Raptor’s Chief Medical Officer.

Raptor has completed pre-submission meetings with the US Food and Drug Administration (“FDA”) and the European Medicines Agency (“EMA”) and is on track to submit marketing applications in both markets in the first calendar quarter of 2012. Raptor plans to file for “Priority Review” in the US and “Accelerated Approval” in the EU. If granted, the Company could potentially receive approval for the sale of RP103 for the treatment of nephropathic cystinosis in both the US and the EU in the fourth calendar quarter of 2012. In anticipation of the potential approval in 2012, Raptor is actively building its US and European commercial infrastructure and pre-commercial programs to market RP103.

About Nephropathic Cystinosis

Nephropathic cystinosis is a rare disease resulting from an inborn metabolic error characterized by the abnormal transport of cystine, an amino acid, out of lysosomes. Poor compliance with current treatments for nephropathic cystinosis can cause serious health consequences, including: renal failure and resultant need for a kidney transplant; growth failure; rickets and fractures; and photophobia and blindness. Symptom onset typically occurs within the first year of life, when cystine crystals accumulate in various tissues and organs, including the kidneys, brain, liver, thyroid, pancreas, muscles and eyes.

Head lice is the second most, infectious disease among children, next to the common cold.

A new drug for lice is coming to the market and a Hot Springs physician spear-headed the research.

The U.S. Food and Drug Administration approved the drug on Tuesday. Head lice are tiny insects that feed and live on the human scalp. They are irritating and can be embarrassing.

“You truly feel like you have bugs crawling in your hair,” says Marci Lawson.

Lawson and her three daughters tried all types of medications.

Hot Springs dermatologist Doctor Dow Stough tested the drug Natroba on Lawson’s family. The lead researcher found it eradicated the bugs and its eggs or nits.
“Eighty four percent of patients only needed a single application and they didn’t have to use a nit comb or pick out the nits,” says Dr. Stough.

Stough says lice have developed resistance to current medications and less than half of patients who use other drugs get rid of the pests.

“It didn’t require combing or require us to do our bedding or spray our house down,” says Lawson.

Natroba is easy to apply. You put it on your scalp for ten minutes. You wash it out and then you’re done.

“I think it will change the way head lice treatment is currently conducted,” says Dr. Stough.

Dr. Stough and his medical team tested it on more than one thousand patients. He says the product is safe and has very little side effects.

“A little bit of scalp irritation and scalp redness was noted in three percent,” says Dr. Stough.

Overall they found positive results. Patients like Lawson stand by it and it can now go on the market.

A doctor has to prescribe Natroba. Indiana company ParaPro invented the product and hopes to put it on the market the first half of this year.

Why Big Pharma Is the New Big Biotech

Biotechnology companies used to be distinguished by their ability to produce complex drugs requiring the culture of living organisms- drugs often based on the manipulation of DNA. Genentech and Amgen were pioneers of this field, producing recombinant human proteins and antibody therapeutics. Their success led to the development of the biotechnology industry.

Today, the biotech industry has become a catchall term encompassing nearly all recently formed drug development companies, regardless of biologics or small molecule drugs; alongside Amgen (AMGN) and Genentech stand Gilead (GILD) and Celgene (CELG), two biotech giants focused on small molecules. The same goes for developmental drug developers of all sizes.

The common theme behind companies termed “biotechs” is the expectation of innovation and above average growth compared to general pharmaceutical companies- and biotech companies delivered. Early investors in companies such as Amgen, Genentech, Gilead, and Celgene were rewarded with tremendous returns. Even during their best years, Big Pharma looked stodgy by comparison.

Big Pharma is now beset on all sides with issues including poor management, patent cliffs, a shifting regulatory environment, and late stage drug failures. Employees have been laid off in the tens of thousands, Sales and R&D have been axed as the companies struggle to rework their business plans in a bid to buy more time until the dark days are over. As a result, stock prices have stagnated.

But Big Biotech has not faired much better of late. Sales across the board for Big Biotech companies have slowed and are expected to continue slowing in the near future. PE multiples have compressed to a level that is now comparable to Big Pharma. Few have had substantial new drug approvals in years with the exception of Amgen with its bone drug, denosumab. In the last two years, an investment in the five largest biotechs would have yielded a 5% gain; an investment in the five largest pharmaceutical companies (excluding Johnson & Johnson (JNJ) due to its strong focus outside pharmaceuticals) would have gained 42%, including dividends, in the same period.

Genentech, seen as perhaps one of the most innovative biotech company — now part of Roche (RHHBY.PK) — is still innovating, but in many cases on new methods of drug lifecycle management rather than developing drugs with novel mechanism. Lifecycle management is a necessary facet of drug development, but the degree of Genentech’s attention to this is telling of its maturity.

Every Big Biotech is busy with lifecycle management. With the exception of Celgene- the youngest of the bunch- they are all fighting patent expirations, just like Big Pharma.

In recent years, Big Pharma, through a combination of internal research and acquisitions, has accumulated as much biotechnology capabilities as any biotech. What is left to differentiate Big Pharma from Big Biotech? In general, Big Pharma is bigger, with higher revenue and a larger market cap. They are also more diversified; some have diagnostics, animal care units, and generics. Also, growth rates are still higher for the large biotechs.

Still, it appears the differences are disappearing fast. Big Biotech is likely to head down a similar path of diversification. Many companies initially focusing on a single or narrow disease area have expanded across multiple areas of focus in a bid for growth. Recently, many have decided to enter the biosimilars (generics) fray. And with the advent of personalized medicine, especially in oncology, nearly all will be in the diagnostics business in one way or another.

There is, however, one more difference- Big Pharma offers outstanding dividends while their counterparts continue to hoard cash. Even as growth has slowed, there is no sign the big biotechs intend on paying dividends any time soon.

In the next few years, Big Pharma will lose tens of billions in sales due to generic competition. This is already reflected in their stock prices. Once sales hit their nadir, a new cycle of growth can begin, albeit from a smaller base. These last few years have provided unique opportunities for Pharma, and they have taken advantage.

The economic crisis has prevented all but a few biotech companies from publicly listing their stocks, making trade sales the most sought after exit strategy of biotech start-ups. Companies that would once have been prime candidates for IPOs instead stayed private or ended up in the arms of Big Pharma. Pharma has used this period to bolster their pipelines and technology, all while slimming down.

In the latest scientific conferences, some of the most interesting and newsworthy discoveries have come from Big Pharma labs or those of their collaborators: Roche’s T-DM1, Pfizer’s (PFE) ALK inhibitor, Bristol Myers Squibb’s (BMY) melanoma vaccine, ipilimumab. They are also on the forefront of combination drug clinical trials and personalized medicines.

Big Pharma is resurgent just as Big Biotech is losing steam. With a web of collaborators ranging from university labs to small biotechs to fellow pharmas, each company is focused on innovation. Perhaps it is time to remove the imaginary line separating Pharma from Biotech, after all, the two are not all that different.

Attorneys general from across the country are urging the U.S. Supreme Court to stop pharmaceutical industry reverse payment agreements, a practice that they say prevent consumers from obtaining low-cost generic versions of brand-name drugs.

Recently-elected California Attorney General Kamala D. Harris is leading the charge with an amicus brief, and is joined by 31 additional states’ attorneys general, the AARP, Consumer Federation of America, and other groups that hope to convince the court to review if drug industry “pay-to-delay” agreements have violated state and federal antitrust laws. The delays potentially cost consumers billions of dollars.

“Keeping generic drugs off the market forces Californians to pay artificially high prices and denies many access to the medication they need,” Harris said in a statement. “Our office is committed to putting an end to anticompetitive schemes like this that drive up drug prices in order to protect pharmaceutical companies’ profits.”

In a case before the Supreme Court, the Bayer Corporation allegedly paid competitors nearly $400 million in 1997, under the guise of settling patent litigation, if they would agree not to market generic versions of the popular antibiotic, Cipro (Ciprofloxacin)—which at the time pulled in an annual $1 billion in sales for Bayer.

Class action lawsuits were filed in New York three years later on behalf of consumers against Bayer and companies that cooperated in the scheme such as Barr Laboratories, Watson Pharmaceuticals, Hoechst Marion Roussel, and the Rugby Group. However, the court ruled in favor of reverse payment agreements as long as they were done in the context of a settling patent litigation, even if the drug patents were no longer valid.

The brief filed earlier this month supports a private antitrust lawsuit filed by direct purchasers of Cipro. The plaintiffs include large drug wholesalers, pharmacies, unions and health care plans.

Supreme Court to hear arguments on drug overcharges

SAN JOSE, Calif. — For the past six years, Santa Clara County, Calif., has led a quiet legal fight to force the drug industry to reimburse local governments across the country allegedly gouged by hundreds of millions of dollars per year on prescription drug prices at public hospitals and clinics devoted to serving the poor.

But the pharmaceutical companies have struck back with a vengeance, unleashing their lawyers to keep the courthouse doors slammed on the legal claims.

Wednesday, local governments and the drug industry will square off over the issue in the U.S. Supreme Court, which ultimately must decide whether obscure provisions in the federal Medicaid program should prevent a lawsuit over the drug overcharging allegations from reaching a judge and jury.

Santa Clara County, which filed the class action lawsuit in 2005 along with Santa Cruz County, faces an uphill fight. Not only are county officials up against the powerful pharmaceutical industry, but also the Obama administration — despite its pledge to cut health care costs — has sided with the drug companies because of concerns that such lawsuits would clutter Medicaid oversight with litigation.

The administration’s position has disappointed county officials, particularly because former County Counsel Ann Ravel, who pushed the lawsuit originally, is now a top lawyer in the civil division of the U.S. Justice Department. The Justice Department’s civil division crafted the friend-of-the-court brief siding with the drug industry. Ravel, who has strongly defended the importance of the lawsuit in the past, declined to comment on her bosses’ position in the case; she was not involved in the legal brief.

Said Jeff Lawrence, one of the private lawyers helping the county in the case: “It’s a big mystery as to why they sided with the drug companies.”

The Supreme Court case stems from a legal battle against at least 10 drug companies, including Bayer, Pfizer and Glaxo. The lawsuit alleged drugmakers were violating a Medicaid drug discount program that primarily serves the poor, failing to comply with provisions that require the companies to give county hospitals and other public health service agencies wholesale discounts of 20 to 35 percent on over-the-counter and prescription medications. In California, Medicaid is known as Medi-Cal.

The federal Office of the Inspector General had concluded pharmaceutical companies overcharged local agencies tens of millions of dollars each year over a six-year period, a cost that comes from taxpayers because the drug program is a safety net for the poor. The report found Santa Clara County was overcharged by more than $6 million in 1999 alone. That report triggered the lawsuit.

The drug companies have denied the overcharges. But the legal fight to date has not focused on the claims of abuses in the Medicaid program.

Instead, the industry argues federal law bars such lawsuits from third parties providing the health care services. A federal judge in San Francisco agreed, dismissing the lawsuit, but it was reinstated in 2008 by the 9th U.S. Circuit Court of Appeals. The Supreme Court agreed to review that ruling.

Lisa Blatt, who is representing the drug industry in the Supreme Court, did not return a phone message and e-mail seeking comment. But in court briefs, she argued that Congress, in creating the drug program, did not provide a right to sue over charging practices, leaving it up to government regulators to handle the task. The U.S. Chamber of Commerce is also backing the industry in the case.

Lawsuits “would seriously interfere with the administration of the … drug ceiling price program, as well as the vastly larger Medicaid drug rebate program,” the drug industry warned.

Santa Clara County argues that there must be a legal way to force drug companies to pay for overbilling. In a twist, the recent health care reforms created a specific administrative procedure for public health providers to pursue such claims for overcharges from January 2010 going forward. But a Supreme Court ruling against the county could prevent efforts to recover for the same conduct that occurred in past years.

The county is backed in the case by three states, a group of law professors and AARP, a nonprofit group that advocates for quality-of-life issues for Americans over age 50.
Mexican online pharmacy
“The good news is that we have a remedy going forward,” Santa Clara County Counsel Miguel Marquez said. “At stake (in the Supreme Court) is, can we recover for the past. The common person on the street is going to say, ‘If they cheated you, there should be a remedy.’ They don’t care about the legal niceties.”